|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.840 USD | +1.97% |
|
-1.60% | +26.15% |
| 06-29 | BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs | RE |
| 06-29 | BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End | MT |
| Market Cap | 2.45B 2.15B 1.97B 1.84B 3.48B 234B 3.54B 23.73B 9.2B 115B 9.21B 9.01B 395B | P/E 2026 * |
-4.26x | P/E 2027 * | 21.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.45B 2.15B 1.97B 1.84B 3.48B 234B 3.54B 23.73B 9.2B 115B 9.21B 9.01B 395B | EV / Sales 2026 * |
3.66x | EV / Sales 2027 * | 3.37x |
| Free-Float |
94.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | +1.97% | ||
| 1 week | -1.60% | ||
| Current month | -1.60% | ||
| 1 month | +14.82% | ||
| 3 months | +4.90% | ||
| 6 months | +26.15% | ||
| Current year | +26.15% |
| 1 week | 9.48 |  | 10.18 |
| 1 month | 8.06 | | 10.94 |
| Current year | 6.23 | | 10.94 |
| 1 year | 6 | | 10.94 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 2025-12-31 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 2025-07-06 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 2026-04-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 2006-12-31 |
Theresa Heggie
BRD | Director/Board Member | 64 | 2018-12-02 |
Charles Gayer
BRD | Director/Board Member | 55 | 2025-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-10 | Free | Director | 48,834 | 0.0192% | ||
| 06-10 | Free | Director | 48,834 | 0.0192% | ||
| 06-10 | Free | Director | 48,834 | 0.0192% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.97% | -1.60% | +9.33% | +39.77% | 2.45B | |
| +3.98% | +10.23% | +73.54% | +132.19% | 56.21B | |
| -3.12% | +5.11% | +71.57% | +94.67% | 55.38B | |
| +3.86% | +8.13% | -9.27% | -9.62% | 23.75B | |
| +4.30% | +7.87% | +14.32% | +428.91% | 23.19B | |
| +3.64% | +10.54% | +39.81% | -4.50% | 18.14B | |
| +4.11% | +9.85% | +42.56% | -27.36% | 16.84B | |
| +2.57% | +20.26% | +181.98% | +355.99% | 15.86B | |
| +3.50% | +5.64% | +28.04% | +192.26% | 13.56B | |
| +7.20% | +10.70% | +42.91% | - | 12.97B | |
| Average | +2.82% | +7.26% | +49.48% | +133.59% | 23.84B | |
| Weighted average by Cap. | +1.99% | +6.11% | +56.61% | +133.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 671M 587M 539M 503M 952M 64B 970M 6.49B 2.52B 31.36B 2.52B 2.46B 108B | 727M 636M 585M 545M 1.03B 69.36B 1.05B 7.04B 2.73B 33.98B 2.73B 2.67B 117B |
| Net income | -570M -498M -458M -427M -808M -54.34B -823M -5.51B -2.14B -26.62B -2.14B -2.09B -91.87B | 101M 88.62M 81.41M 75.89M 144M 9.66B 146M 980M 380M 4.73B 380M 372M 16.33B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-02 | US$9.840 | +1.97% | 4,858,293 |
| 26-07-01 | US$9.650 | -3.50% | 4,866,525 |
| 26-06-30 | US$10.00 | +4.71% | 7,719,752 |
| 26-06-29 | US$9.550 | -3.92% | 6,533,643 |
| 26-06-26 | US$9.940 | +0.40% | 10,986,513 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
